|Bid||3.9000 x 3100|
|Ask||4.0600 x 1300|
|Day's range||3.7800 - 4.4100|
|52-week range||2.9100 - 14.7300|
|Beta (5Y monthly)||1.79|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.83|
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
BEDFORD, Mass., June 08, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced senior leadership changes to strengthen the Company’s alignment around the development of its late-stage ophthalmology product portfolio. The realignment was affected to enhance Ocular’s ability to execute its strategy of building a comprehensive portfolio of asse
BEDFORD, Mass., June 01, 2022--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM ET at the Marriott Marquis in New York, NY.